高级检索
当前位置: 首页 > 详情页

Treatment of colon cancer with oncolytic herpes simplex virus in preclinical models

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Huazhong Univ Sci & Technol,Tongji Med Coll,Tongji Hosp,Dept Gastrointestinal Surg,Wuhan 430074,Peoples R China [2]Hubei Univ Technol, Hubei Prov Cooperat Innovat Ctr Ind Fermentat, Wuhan, Peoples R China [3]Chinese Acad Med Sci, Canc Inst & Hosp, Dept Blood Transfus, Beijing 100730, Peoples R China [4]Peking Union Med Coll, Beijing 100021, Peoples R China [5]Third Hosp Wuhan City, Dept Plast & Aesthet Surg, Wuhan, Peoples R China [6]Chinese Acad Med Sci, Canc Inst & Hosp, Dept Immunol, Beijing 100730, Peoples R China [7]Huazhong Univ Sci & Technol, Tongji Med Coll, Puai Hosp Wuhan City, Dept Geriatr Med, Wuhan 430074, Peoples R China [8]Hubei Univ Sci & Technol, Sch Pharmacol, Xianning, Peoples R China
出处:
ISSN:

摘要:
Cancer stem cells (CSCs), which are a rare population in any type of cancer, including colon cancer, are tumorigenic and responsible for cancer recurrence and metastasis. CSCs have been isolated from a number of different solid tumors recently, although the isolation of CSCs in colon cancer is still challenging. We cultured colon cancer cells in stem cell medium to obtain colonosphere cells. These cells possessed the characteristics of CSCs, with a high capacity of tumorigenicity, migration and invasion in vitro and in vivo. The isolation and identification of CSCs have provided new targets for the therapeutics. Oncolytic herpes simplex viruses (oHSV) are an effective strategy for killing colon cancer cells in preclinical models. Here, we examined the efficacy of an oncolytic herpes simplex virus type 2 (oHSV2) in killing colon cancer cells and colon cancer stem-like cells (CSLCs). oHSV2 was found to be highly cytotoxic to the adherent and sphere cells in vitro, and oHSV2 treatment in vivo significantly inhibited tumor growth. This study demonstrates that oHSV2 is effective against colon cancer cells and colon CSLCs and could be a promising strategy for treating colon cancer patients.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2015]版:
大类 | 2 区 医学
小类 | 2 区 生物工程与应用微生物 3 区 生化与分子生物学 3 区 遗传学 3 区 医学:研究与实验
最新[2025]版:
大类 | 3 区 医学
小类 | 2 区 生物工程与应用微生物 3 区 生化与分子生物学 3 区 遗传学 3 区 医学:研究与实验
JCR分区:
出版当年[2014]版:
Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Q2 MEDICINE, RESEARCH & EXPERIMENTAL Q2 GENETICS & HEREDITY Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY
最新[2023]版:
Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Q1 GENETICS & HEREDITY Q2 MEDICINE, RESEARCH & EXPERIMENTAL

影响因子: 最新[2023版] 最新五年平均 出版当年[2014版] 出版当年五年平均 出版前一年[2013版] 出版后一年[2015版]

第一作者:
第一作者单位: [1]Huazhong Univ Sci & Technol,Tongji Med Coll,Tongji Hosp,Dept Gastrointestinal Surg,Wuhan 430074,Peoples R China [2]Hubei Univ Technol, Hubei Prov Cooperat Innovat Ctr Ind Fermentat, Wuhan, Peoples R China
通讯作者:
通讯机构: [2]Hubei Univ Technol, Hubei Prov Cooperat Innovat Ctr Ind Fermentat, Wuhan, Peoples R China [8]Hubei Univ Sci & Technol, Sch Pharmacol, Xianning, Peoples R China [*1]Hubei Univ Technol, Innovat Ctr Ind Fermentat, Hubei Prov Cooperat, Wuhan, Hunan, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:428 今日访问量:2 总访问量:412 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)